Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Denbury Resources Inc. (DNR - Analyst Report) has reported first-quarter 2012 adjusted earnings of 41 cents per share (excluding one-time items), beating our expectation of 38 cents. The quarterly results were also well above the year-earlier adjusted earnings of 26 cents, attributable to record output from tertiary oil and the Bakken output.
Total revenue jumped 35% to $645.1 million from the year-ago level of $514.2 million and comfortably surpassed the Zacks Consensus Estimate of $610 million.
Operational Performance
During the quarter, production averaged 71,532 barrels of oil equivalent per day (Boe/d), up 12% year over year, attributable to the increased output in Bakken and tertiary. Oil production averaged 66,857 barrels (up 14% from the year-ago level) and natural gas averaged 28,052 thousand cubic feet (down 9%), on a daily basis.
Oil price realization (including the impact of hedges) averaged $101.16 per barrel in the quarter, showing an improvement of 9% year over year, while gas prices decreased 8% to $6.59 per Mcf. On an oil equivalent basis, the overall price realization was $97.14 per barrel, up 10% from the year-earlier level of $88.70 per barrel.
Financials
Cash flow from operations was $291.7 million in the reported quarter versus $124.8 million in the year-ago quarter. Oil & natural gas capital investments were $302.8 million, up from the year-earlier level of $220.1 million. Denbury's 2012 capital expenditure budget has been hiked by $150 million to $1.5 billion. Of the $150 million increase, $80 million is allocated for Bakken development while the remainder will be expended toward tertiary floods.
Cash balance as of March 31, 2012was $77.4 million and long-term debt was $2,496.4 million, representing a debt-to-capitalization ratio of 33.6% (unchanged from the preceding quarter).
Outlook
With its own in-house CO2 reserve base, Denbury enjoys a significant competitive advantage in acquiring and exploiting mature oil reservoirs. Tertiary operations remain the company's principal focus with particular emphasis on the Gulf Coast, Rocky Mountains and Bakken Shale holdings.
Denbury reduced its 2012 production guidance to 68,625–73,625 Boe/d from its earlier estimate of 70,250–75,250 Boe/d. The company’s tertiary production target remains unchanged in the 33,000–36,000 Boe/d range, while the Bakken production guidance has been increased to the range of 14,350–16,350 Boe/d from 12,750–14,750 Boe/d previously.
However, we see limited upside potential for Denbury shares due to its sensitivity to oil price volatility, along with drilling results, costs, geo-political risks and project timing delays. Additionally, competition from Pioneer Natural Resources (PXD - Analyst Report) and Newfield Exploration Co. (NFX - Analyst Report) is also a cause for concern.
We currently reiterate our long-term Neutral rating on Denbury shares. The company carries a Zacks #2 Rank (short-term Buy rating).
Get the full Analyst Report on DNR - FREE
Get the full Analyst Report on PXD - FREE
Get the full Analyst Report on NFX - FREE